




RealRate

PHARMACEUTICAL 2018

Oncternal Therapeutics Inc.
Rank 232 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

Oncternal Therapeutics Inc. Rank 232 of 349

The relative strengths and weaknesses of Oncternal Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 274% points. The greatest weakness of Oncternal Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -301%, being 23% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	46,077
Cost of Goods Sold	0
Intangible Assets	108
Liabilities, Current	7,975
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	216
Property and Equipment	51
Research and Development	21,467
Revenues	0
Selling, General and Administrative Expense	9,188

Output Variable	Value in 1000 USD
Assets	46,236
Liabilities	7,975
Expenses	30,655
Stockholders Equity	38,261
Net Income	-30,439
Comprehensive Net Income	-30,439
Economic Capital Ratio	-301%

